Trefoil factor-2, an early predictor for acute gastrointestinal injury in patients with acute pancreatitis

Abstract

Abstract Acute gastrointestinal injury (AGI) is commonly present in patients with acute pancreatitis (AP). It is often difficult to predict gastrointestinal function in the early stage due to lack of reliable markers. We aimed to assess whether early plasma trefoil factor 2 (TFF-2) is a potential predictor for AGI. Fifty one patients were included for the onset of AP (from developing abdominal pain) within 72\u200ahours in this prospective observational single-center study from January 2013 to July 2015. Among them 23 patients were classified as mild, 17 as moderately severe, and 11 as severe according to 2012 Atlanta classification. Plasma samples were collected only once at admission to the ICU. Twenty samples of healthy adults were also collected as control. The TFF-2 levels were determined by using a human TFF-2 enzyme-linked immunoassay. AGI grades from 1st to 7th day after admission were observed. The plasma TFF-2 levels among AP patients in early stage were significantly higher than healthy controls (766.41\u200ang/mL vs 94.37\u200ang/mL, P\u200a<\u200a.0001). The correlations between TFF-2 levels and AGI grades from 1st to 4th day after admission were positive (r\u200a=\u200a0.47, 0.43, 0.42, 0.40 respectively, P\u200a<\u200a.05). As a predictor of acute gastrointestinal failure, plasma TFF-2 was superior to others: Acute Physiology and Chronic Health Evaluation II, sequential organ failure assessment, procalcitonin, C-reactive protein, serum calcium. In addition, TFF-2 increased along with the severity of AP (r\u200a=\u200a0.554, P\u200a<\u200a.0001) and associated with Acute Physiology and Chronic Health Evaluation II, sequential organ failure assessment, C-reactive protein, serum calcium. The plasma TFF-2 levels were increased in patients in early stage of AP and correlated with AGI grades and disease severity in our study. TFF-2 might be a potential predictor for acute gastrointestinal failure in patients with AP.